{"slug":"parp","tag":"parp","variants":["parp"],"description":"No description yet","count":8,"kinds":{"person":8},"related":[{"slug":"ovarian","tag":"ovarian","shared":4},{"slug":"adc","tag":"adc","shared":1},{"slug":"brca","tag":"brca","shared":1},{"slug":"discovery","tag":"discovery","shared":1},{"slug":"dna-repair","tag":"dna-repair","shared":1},{"slug":"hrd","tag":"hrd","shared":1},{"slug":"pancreatic","tag":"pancreatic","shared":1},{"slug":"prostate","tag":"prostate","shared":1},{"slug":"resistance","tag":"resistance","shared":1},{"slug":"surgery","tag":"surgery","shared":1},{"slug":"swog","tag":"swog","shared":1},{"slug":"synthetic-lethality","tag":"synthetic-lethality","shared":1}],"records":[{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/","tldr":"Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers."},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","tldr":"Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346."},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","tldr":"Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit."},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/","tldr":"Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers."},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","tldr":"Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer."},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/","tldr":"Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer."},{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","route":"/people/thomas-helleday/","tldr":"Co-discovered that PARP inhibitors kill BRCA-deficient cells, the synthetic lethality behind olaparib and its successors."},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/","tldr":"Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors."}]}